You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

  • Technology appraisal guidance
  • Reference number: TA589
  • Published:  24 July 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Notes
  5. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 157 KB)

    Published:
    24 July 2019

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 335 KB)

    Published:
    19 June 2019
  • Committee papers (PDF 4.99 MB)

    Published:
    19 June 2019

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF 281 KB)

    Published:
    06 March 2019
  • Committee papers (PDF 11.19 MB)

    Published:
    06 March 2019
  • Public committee slides (PDF 475 KB)

    Published:
    06 March 2019

Notes

  • Note

  • Note

  • Note

  • Note

  • Note

Invitation to participate

  • Final scope (PDF 234 KB)

    Published:
    06 June 2017
  • Final matrix (PDF 261 KB)

    Published:
    06 June 2017
Back to top